Amlodipine (besylate)

Amlodipine besylate (Amlodipine benzenesulfonate), an antianginal agent and an orally active dihydropyridine calcium channel blocker, works by blocking the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine besylate can be used for the research of high blood pressure and cancer^[1][2][3]. IC50 & Target: L-type calcium channel^[1] In Vitro: Amlodipine besylate (20-40 μM; 48 h) reduces BrdU incorporation to 68.6% and 26.3% at concentrations of 20 and 30 μM in A431 cells, respectively^[3].
Amlodipine besylate (30 μM; pretreated for 1 h) significantly attenuates the uridine 5′-triphosphate (UTP)-induced increases of [Ca²⁺]_i in A431 cells^[3].
Amlodipine besylate (30 μM) inhibits the store-operated Ca²⁺influx evoked by Thapsigargin in Fluo-3-loaded cells^[3]. In Vivo: Amlodipine besylate (5 mg/kg/day; s.c. for 2 weeks) significantly decreases systolic blood pressure (SBP) in VSMC ATP2B1 KO mice^[4].
Amlodipine besylate (10 mg/kg; i.p. once daily for 20 days) causes a significant retardation of tumor growth and prolongs the survival of A431 tumor-bearing mice^[3].